Background: Worldwide, human papillomavirus (HPV) 16 and 18 represents 70% of high-risk (HR) HPV found in cervical cancer. However HIV-positive women are more frequently infected by HRHPV other than HPV 16 or 18 (OHR). We aimed to analyse the HRHPV genotype distribution in a cohort of HIV-positive women and to estimate the potential protection offered by the different HPV vaccines.
Introduction
Persistent infection with 13 human papillomavirus (HPV) genotypes called at high risk (HR) induces invasive cervical cancer (ICC) [1] . Worldwide HPV genotype 16 and 18 represents 70% of the HRHPV found in cervical cancer in the general population; however, HRHPV distribution may vary according to cytology and geographical regions [1] [2] [3] . In HIV-positive women, infection with these HRHPV and HPV-induced lesions ranging from low grade (L) squamous intraepithelial lesions (SIL) to ICC are more frequent, more severe and have a worst outcome than in HIV-negative women [4, 5] ; moreover, HIV-positive women display a different HRHPV genotype distribution with less infection caused by HPV16 but more infection due to HRHPVother than 16 [6] . Since 2007, two prophylactic vaccines (the bivalent and the quadrivalent vaccines) have been licensed to prevent HRHPV infection and subsequent dysplasia or ICC caused by HPV 16 and 18. Guidelines such as those from ACIP and WHO recommend to vaccinate HIVpositive girls and young women against HPV because of the heavier burden of HPV infection and associated diseases [7, 8] . A new ninevalent vaccine protecting against HPV16 and 18 and five additional HRHPV genotypes (31/33/45/52/58) has been approved by the FDA in December 2014 and by the European Medicines Agency in June 2015 [9] . In this context, it is essential to characterize the HPV genotypic distribution in HIVpositive women before establishing the best vaccine option.
Several European studies have looked at HRHPV distribution in HIV-positive patients but none in Belgium where it is estimated that 5700 women live with HIV [10] . The Belgian HIVepidemics is characterized by a significant proportion of patients acquiring HIV through heterosexual contacts; among them, the majority are from Central Africa and 50% are women [10, 11] . Consequently, we made the hypothesis that the HRHPV epidemiology in HIV-positive women living in Belgium could be linked with its African origin and might differ from other European countries. Between 2002 and 2012, we conducted a prospective cohort study to characterize the epidemiology of HRHPV infection and associated diseases among women followed in our AIDS Reference Centre in Brussels. We present here the analysis on a subset of 508 patients with HPV genotyping determination.
Methods
From 2002 to 2012, a prospective programme of screening and follow-up of HRHPV infection was offered to all women followed for HIV-1 infection in the Saint-Pierre University Hospital AIDS Reference Centre in Brussels. Women were seen annually by a dedicated gynaecologist for HPV detection and cytology on Pap smear on liquid-based sample (SurePath; BD, Franklin Lakes, New Jersey, USA) taken with cytological brush. In cases of abnormal cytology [defined as ICC or SIL of any grade or atypical squamous cells of unknown origin (ASCUS) or that cannot exclude high-grade SIL (ASCH)] women underwent colposcopy and cervical biopsy. Surrogate markers of HIV infection were retrieved from the Saint-Pierre HIV Cohort database. [12, 13] .
From March 2011 to December 2012, HRHPV was detected by PCR (Abbott RealTime High Risk HPV; Abbott Park, Illinois, USA) in 508 women: 237 had been enrolled in the cohort before March 2011 (so they were screened by hybrid capture up to March 2011 and then by PCR after this date) and 271 were included for the first time with HPV detection by PCR. In the present work, we only took into account the results of screens performed by PCR. PCR results were classified as HPV16, HPV18 or other HRHPV (OHR).
Samples from patients with OHR were frozen to further subtype HRHPV later on by Clart HPV2 (Genomica, Madrid, Spain).
Cervical cytology and biopsies were sampled according to standard diagnostic technique performed routinely and defined according to the revised 2001 Bethesda Classification for cervical cytology [14] . When both cytology and biopsy were performed at the same time and differed, results from the biopsy were considered.
Among women infected by HRHPV, we looked if there were specific risk factors associated with infection by HPV16, HPV18 or OHR; we compared the different epidemiological characteristics, the immunity levels and the HIV treatment data of the different groups by univariate (by Fisher's exact or Kruskal-Wallis test) then multivariate analyses (by logistic regression).
To evaluate the prevalence rates for the different HRHPV genotypes according to the cervical cytology, we calculated a minimum and a maximum estimates as described by others [15] . Minimum estimates include all cases infected by a single HRHPV genotype for a cervical disease category; this approach attributes a specific cytological category to the single HRHPV genotype present. Maximum estimates consist of all cases infected by a specific genotype whether infection is caused by this single type or by multiple types including this specific genotype; this maximum estimates takes into account cases infected by multiple HPV genotypes. To take an example among 20 patients with HSIL, if HPV16 is found as single infection in three women and as part of multiple infection (by HPV16 plus OHR) in seven women, minimum estimates for HPV16 prevalence in HSIL will be 15% (3/20) and maximum estimates 35% (7/20) .
We compared the proportion of women who could have been protected against ICC or its precursors induced by HRHPV genotypes found in their screen if they had received any of the current prophylactic vaccines against HPV: either the first generation vaccines (bivalent or quadrivalent) that protect against HPV16/18 or the second generation vaccine (ninevalent) that protects against HRHPV genotypes HPV16/18/31/33/45/52/ 58. To estimate the proportion of women protected by the vaccine, we used two different approaches. The first one, ''the optimistic scenario'', considers that, if a woman is infected with several genotypes, she could benefit from vaccination if at least one of her genotypes is included in the vaccine. The second scenario, ''the conservative scenario'', considers that a woman is protected by the vaccine only if all her HRHPV genotypes are included in this vaccine.
Results
Among 508 women screened by PCR, seven had previous hysterectomy for non-cancerous reason and 78 had high-grade cervical intraepithelial neoplasia (HGCIN) or ICC; however, we did not exclude them from the complete picture of the genotype distribution.
The cohort characteristics
The characteristics of these 508 women at time of first PCR screening were: African (84%) or Caucasian (16%) origin, median age 42 years (interquartile 25-75: 35-48 years), median CD4 þ T-cells count 555 cells/ml; HIV acquired through heterosexual relations (89%), blood transfusion (2.6%), mother-to-child transmission (1.8%) and intravenous drug use (1.4%). Eighty-nine percentage were on antiretroviral treatment (median duration 74 months) and 73% had HIVRNA less than 20 copies/ml. We compared these characteristics according to whether the patient had been enrolled before or after March 2011 ( Table A in the Annex/supplement, http://links.lww.com/QAD/A807). At time of first PCR screening, the two groups of patients were similar in terms of age, ethnic origin, risk factor for HIV acquisition, Centers for Diseases Control (CDC) AIDS stage, smoking habits and median CD4 þ cell count nadir. Women screened after March 2011 had a slightly higher median CD4 þ cell count, were more frequently on cART and had more frequently a viral load less than 50 cp/ml.
High-risk human papillomavirus prevalence
Prevalence of HRHPV infection was 23% (116/508). Among women with HRHPV, 44 (38%) had abnormal cytology or histology including high-grade SIL (HSIL) in 12 (10%). OHR were found in 101 subjects (87%): 88 women (76%) without HPV16 or HPV18 and 13 (11%) with either HPV16 (n ¼ 5; 4%) or HPV18 (n ¼ 8; 7%). HPV16 was found as a single infection in six women (5%) and HPV18 in nine (8%). HRHPV genotypes distribution was similar in the 15 Caucasian and the 101 African women (P ¼ 0.75, Fisher's exact test). Single infection were found in Caucasian and African women respectively in 0 and 6% for HPV16, in 7 and 8% for HPV18 and in 87 and 74% for OHR; mixed infection by OHR plus HPV16 were detected respectively in 7 and 4% and by OHR plus HPV18 in 0 and 8% of the patients.
Patients' characteristics according to human papillomavirus 16, 18 or other high-risk human papillomavirus
We compared the characteristics of 116 HRHPVinfected women according to whether they were infected by HPV16 or not, by HPV18 or not or by OHR or not (Table 1) . In univariate analysis, infection by HPV16 was significantly associated with being less than 35 years or having a lowest median nadir CD4 þ cell count (100/ml). In multivariate analysis, being more than 35 decreased the risk of being infected by HPV16 (odds ratio 0.23; 95% confidence interval 0.06-0.89, P ¼ 0.03 by logistic regression). Infection by HPV 18 was not associated with any of the risk factors. Infection by OHR was significantly associated with previous AIDS stage C according to the CDC classification: 27% of women with OHR had had a previous AIDS event compared with none among women infected by HPV 16 or 18 (P ¼ 0.02 by univariate analysis).
High-risk human papillomavirus genotypes according to cervical cytology HRHPV specific genotypes prevalence rates found in each cervical cytology category are detailed in Table 2 and Fig. 1 : prevalence rates of HPV16, HPV18 or OHR were significantly higher in cases of abnormal vs. normal cytology. In case of HSIL, HPV16 and OHR were significantly more present.
High-risk human papillomavirus genotype distribution
To calculate the prevalence rates of HPV16, 18 or OHR, we divided the total number of women having each of these three subtypes by 116 (the total number of women infected by HRHPV). Among women infected with OHR, further subtyping was achieved in 80% of samples (79/99); it was not feasible in the remaining 20% (20/99) due to repeated manipulations and extractions. A median number of two HRHPV genotypes were found in each sample. We divided the number of women with each specific OHR genotypes by 79; we then multiplied this result by 0.87 (which is the proportion of women with OHR among the 116 patients) and obtained an estimation of prevalence that could be found in the 101 OHR-infected women if they had all been subtyped: HPV52 (19.8%), HPV18 (14.6%), HPV31 (12.1%), HPV35 (12.1%), HPV51 (12.1%), HPV58 (12.1%), HPV56 (9.9%), HPV16 (9.5%), HPV33 (8.8%), HPV59 (6.6%), HPV68 (5.5%), HPV39 (2.2%), HPV45 (1.1%).
Preventable fraction of High-risk human papillomavirus by vaccination
Regarding the preventable fraction of HRHPV infection by vaccination, according to the 'optimistic scenario', (Table 3 ).
Discussion
In this prospective observational cohort of women with a median age of 42 years and fully suppressed HIV viremia for several years, the prevalence of cervical HRHPV infection was 23%. This high prevalence that we previously described is greater than what is usually found in Europe and is comparable to rates from other sub-Saharan African cohorts. In a previous publication, we have been able to stratify precisely the HRHPV prevalence according to the age and the immunity level strata at time of HRHPV screen among 652 women enrolled between January 2002 and February 2011. In this model, a median age of 42 years and 555 CD4 þ T-lymphocytes/ml is significantly associated with a HRHPV prevalence of 22%, which is close to the 23% that we indeed found in the subset of 508 women screened by PCR since March 2011 [13] .
We found that HRHPVother than 16 and 18 were highly prevalent both in women with normal cytology and with dysplastic lesions including HSIL. The most frequent HRHPV types were HPV52 (19.8%), HPV18 (14.6%), HPV31/35/51/58 (12.1%), HPV56 (9.9%) and HPV16 (9.5%). Compared to what has been found in 9300 HIVnegative Belgian women screened by PCR, rates in our cohort are much lower for HPV16 and much higher for HPV18 but similar for HPV 31/51/52 [16] . In the LGSIL & ASCUS (n = 32) HGSIL (n = 12) % Fig. 1 . Prevalence rates of HRHPV-specific genotypes found in each cervical cytology category by minimum (min) and maximum (max) estimates.
European general population, the most frequent HRHPV found in a meta-analysis including 33 000 women with normal cytology were HPV16 (23%), HPV31 (11.4%) and HPV 18/33/52 (8% each). In 6600 women with HSIL and ICC, HPV16 was also the most prevalent (respectively 54% for HSIL, 67% for ICC) followed by HPV18 (respectively 8%, 16.4%) [3] .
The distribution of genotypes in our cohort also differs from other European HIV cohorts where HPV16 or 31 are the most prevalent although age and HIV surrogate markers are very similar to ours [6, 17, 18] ; these cohorts are characterized by a higher proportion of women with HIVacquired by intravenous drug use (from 21.5 to 34%). Compared to the results of a meta-analysis on HRHPV genotypes according to cervical cytology and geographical regions in 5578 HIV-positive women worldwide, the distribution in the Saint-Pierre cohort is a mix of a higher prevalence of HPV 35, 51 and 52 like in sub-Saharan Africa and rates of HPV 18, 31 and 59 comparable to what is found in Europe and North America [6] . The most frequent HRHPV genotypes found in our cohort are also similar to those detected in HIV-positive women enrolled in recent studies in Central Africa (Table 4 ) [19] [20] [21] [22] [23] [24] [25] . As the majority of women included in our cohort are from sub-Saharan African origin, they could have been infected by HRHPV in Africa before coming to Europe or in Europe by African sexual partners carrying these specific HRHPV genotypes. Indeed, several studies showed that migrants retain a higher risk of sexually transmitted infections (STIs), including HPV infection, from their native countries several years after arrival in another country with a lower prevalence and incidence for these STIs [26] .
It is intriguing to find that the genotypes distribution was not different for Caucasian women in our cohort. One hypothesis might be that they might have been in contact with HIVand HPV coming from Africa after intercourses with African partners or Caucasian partners having lived in Africa or previously in contact with African partners. In Belgium, a significant part of the HIV epidemic is due to heterosexual transmission in both African and Caucasian persons due to the close link between Belgium and Central Africa [10, 11] . To assess that, we looked at HIV clades of Caucasian women in our cohort (data not showed) and found that 57% had indeed an African HIV clade suggesting that these women might have acquired both HIV and HPV African-specific subtypes.
Beyond the sexual behaviour explanation, could genetic differences play a role in the different HRHPV genotypes distribution? Sudenga et al. have shown that genetic variants of the major histocompatibility complex had different influences on the ability to clear HRHPV infection in HIV-positive women [27] . One of these variants was significantly associated with African-American origin. Finally, degree of immunosuppression could also play a role in genotype distribution: there is indeed an inverse relationship between lower CD4 þ T-cell count and higher cervical prevalence of most HRHPV types but this relation is less marked for HPV16 [28] . This suggests that the ability to avoid immune surveillance gives HPV16 an advantage against other HRHPV in immunocompetent women but not in immune depressed patients.
These findings have significant implications on the potential protection offered by the different prophylactic vaccines against HPV. HPV 16 and 18 are present in only 27% of our patients which is in line with maximum a third of HIV-positive women in other sub-Saharan African studies (Table 4 ). Although HPV 16 or 18 prevalence increases when cytological abnormalities progress from mild to severe dysplasia or cancer in both HIV-positive and negative populations, other HRHPV such as 31/51/ 52/58 are more frequently detected in HSIL in HIVinfected women [3, 6] . Similarly, among genotypes retrieved from high-grade anal intra epithelial (HGAIN) biopsies from 363 HIV-positive MSM, only 56% the patients harboured a genotype covered by the bivalent or quadrivalent vaccines [15] . Our results confirm observations that vaccines protecting against HPV 16 and 18 could prevent only a fraction of HRHPV infection and dysplasia in populations at greater risk for HPV such as HIV-positive patients or patients with African ethnic origin. In fact, only half of the HIV-negative African-American women with HRHPV might be covered by 430 AIDS 2016, Vol 30 No 3 Table 3 . Proportion of women infected with HRHPV genotypes that could be protected by either the bi-and quadrivalent vaccines or by the ninevalent vaccine according to two approaches. (21) n, number of patients. these early generation vaccines in the USA [29, 30] . On the contrary, the new ninevalent vaccine, which includes genotypes 16/18/31/33/45/52/58, could offer protection in a significantly higher proportion of patients, namely in 89% of HIV-positive men from the HGAIN study and in 82% in our cohort of HIV-positive women. This result was estimated according to an 'optimistic scenario' considering that a woman is protected by a vaccine if at least one of her HRHPV genotypes is included in the vaccine. However, this analysis may overestimate the protection offered by the different vaccines in particular in woman with multiple HRHPV infection. If we use a more 'conservative scenario' where a woman with mixed infection is considered protected only if all her HRHPVare included in the vaccine, we still find a protection around four to six times higher with the ninevalent vaccine compared with others.
Proportion of women covered by
Our study has limitations and strengths. Allocation of a specific HPV genotype to a lesion can be delicate in case of infection by several HRHPV. We have used an approach validated by others. All comparisons between genotypes distribution retrieved from different studies should be interpreted with caution as trials differ in population characteristics (age, presence of cytological abnormalities, HIV surrogate markers or treatment) and in techniques to detect HPV that might underestimate some genotypes such as HPV18. The strengths of our research are the size of our cohort including 508 women and the fact that we could classify all women according to the presence or absence of HPV16, 18 or OHR. We could also determine the specific genotype in 80% of our OHR; in this group, we cannot exclude the unlikely full discrepancy between those that have been successfully genotyped (n ¼ 79) and those that could not be genotyped (n ¼ 20). However, even in case of this very improbable event, they only represent 18% (21/116) of the whole HRHPV-infected group so it should not significantly impact on the results.
The HRHPV genotypes distribution found in this cohort of women living in Europe with a successfully treated HIV infection for several years is similar to the one found in Central Africa even in women of Caucasian origin. In this population of HIV-positive women, the bivalent or the quadrivalent vaccines including HRHPV 16 and 18 could offer protection in only 30% of the subjects; in contrast this protection could be extended up to 80% with the ninevalent vaccine covering for HRHPV 16/18/31/ 33/45/52/58. Vaccination guidelines should take into account these specific epidemiological characteristics to propose the best strategy.
